Skip to main content
. 2018 Apr 5;20(10):1411–1418. doi: 10.1093/neuonc/noy054

Fig. 3.

Fig. 3

Kaplan–Meier plots showing the association between confirmed volumetric response (VR) and OS in recurrent GBM patients treated with cabozantinib. (A) Kaplan–Meier plots demonstrating a significant survival advantage in patients with a confirmed VR treated with cabozantinib pooled across both 100 mg and 140 mg dose levels (log-rank, P < 0.0001, HR = 0.3050). (B) Kaplan–Meier survival plots showing a significant survival advantage in patients with confirmed VR treated with 100 mg and 140 mg. Note that patients with confirmed response treated with 140 mg had a significantly longer OS compared with volumetric responders treated with 100 mg (log-rank, P = 0.0211).